Busulfan manufacturers & suppliers

Busulfan

Form: Injection (IV), Oral Tablet

Strength: Injection: 6 mg/mL; Tablet: 2 mg

Reference Brands: US: Busulfex® (IV), Myleran® (oral); EU: Busilvex® (IV), Myleran® (tablet)

Category: Oncology Cancer Care

Busulfan, available in 6 mg/mL IV injection and 2 mg oral tablets, is a critical alkylating agent used in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT). Approved in both the US and EU under brands like Busulfex® and Busilvex®, it plays a key role in treating chronic myelogenous leukemia (CML) and other hematologic cancers. Manufactured under strict GMP conditions, Busulfan is supplied in sterile, ready-to-infuse formulations, making it ideal for oncology-focused B2B partnerships, licensing, and supply in regulated markets. Reliable sourcing of Busulfan is essential for transplant protocols in cancer care facilities.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Atezolizumab

Strength: 1200 mg/20 mL

Form: Intravenous infusion

Reference Brands: Tecentriq® (EU & US)

View Details
Durvalumab

Strength: 120 mg/4 mL, 500 mg/10 mL

Form: Injection

Reference Brands: Imfinzi® (US & EU)

View Details
Sunitinib

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Form: Tablet

Reference Brands: Sutent® (EU & US)

View Details
Ifosfamide

Strength: 1 g/vial,2 g/vial, 3 g/vial

Form: Injection

Reference Brands: Ifex® (US), Holoxan® (EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.